Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02611154 · ClinicalTrials.gov registry record · Phase 4
Intranasal Delivery of Testosterone and Its Effect on Doping Markers
A Phase 4 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT02611154: Completed Phase 4 study, sponsored by University of Utah.
NCT02611154 is a Phase 4 study that has completed, run by University of Utah. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02611154, a Phase 4 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
Hypothesis: Intranasal administration of exogenous testosterone results in a characteristic profile during anti-doping testing, which is different than the profile seen when testosterone is administered into muscle, on skin or under the tongue. Objective: The investigators aim to characterize the unique steroid doping profile following administration of intranasal testosterone to healthy, active volunteer subjects.
Primary Outcome
Participants were instructed to follow this dosing pattern: Begin taking Intranasal Testosterone at Day 1 for 5 consecutive days (Days 1-5), then to take 2 days off (Day 6 and 7) Urine sample at Day 6 Begin taking Intranasal Testosterone at Day 8 for 5 consecutive days (Days 8-12), then to take 3 days off (Day 13, Day 14, Day 15) Urine sample at Day 13 Begin taking Intranasal Testosterone at Day 16 for 5 consecutive days (Days 16-20), then to take 2 days off (Day 21 and 22) Urine sample at Day
Interventions
- DRUG Testosterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-11-18 |
| Est. Completion | 2016-01-19 |
| Phase | Phase 4 |
What the finished NCT02611154 record still lists
NCT02611154 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Testosterone is the first listed.
NCT02611154 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02611154 about?
NCT02611154 is a clinical study titled "Intranasal Delivery of Testosterone and Its Effect on Doping Markers". Hypothesis: Intranasal administration of exogenous testosterone results in a characteristic profile during anti-doping testing, which is different than the profile seen when testosterone is administered into muscle, on skin or under the tongue. Objective: The investigators aim to characterize the u...
What is the current status of trial NCT02611154?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2015-11-18. Estimated completion is 2016-01-19.
What interventions are being tested in trial NCT02611154?
The interventions under investigation include: Testosterone (DRUG).
Who is sponsoring clinical trial NCT02611154?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02611154's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI